In response to the challenges presented by the unreliable identity of the master node,high communication overhead,and limited network support size within the Practical Byzantine Fault-Tolerant(PBFT)algorithm for conso...In response to the challenges presented by the unreliable identity of the master node,high communication overhead,and limited network support size within the Practical Byzantine Fault-Tolerant(PBFT)algorithm for consortium chains,we propose an improved PBFT algorithm based on XGBoost grouping called XG-PBFT in this paper.XG-PBFT constructs a dataset by training important parameters that affect node performance,which are used as classification indexes for nodes.The XGBoost algorithm then is employed to train the dataset,and nodes joining the system will be grouped according to the trained grouping model.Among them,the nodes with higher parameter indexes will be assigned to the consensus group to participate in the consensus,and the rest of the nodes will be assigned to the general group to receive the consensus results.In order to reduce the resource waste of the system,XG-PBFT optimizes the consensus protocol for the problem of high complexity of PBFT communication.Finally,we evaluate the performance of XG-PBFT.The experimental results show that XG-PBFT can significantly improve the performance of throughput,consensus delay and communication complexity compared to the original PBFT algorithm,and the performance enhancement is significant compared to other algorithms in the case of a larger number of nodes.The results demonstrate that the XG-PBFT algorithm is more suitable for large-scale consortium chains.展开更多
Acute respiratory distress syndrome(ARDS)is characterized by the severe inflammation and destruction of the lung aireblood barrier,leading to irreversible and substantial respiratory function damage.Patients with coro...Acute respiratory distress syndrome(ARDS)is characterized by the severe inflammation and destruction of the lung aireblood barrier,leading to irreversible and substantial respiratory function damage.Patients with coronavirus disease 2019(COVID-19)have been encountered with a high risk of ARDS,underscoring the urgency for exploiting effective therapy.However,proper medications for ARDS are still lacking due to poor pharmacokinetics,non-specific side effects,inability to surmount pulmonary barrier,and inadequate management of heterogeneity.The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery.Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy,which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment.Through passive,active,or physicochemical targeting,nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment,thereby showing good therapeutic activity and reduced toxicity.This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy,highlights the strategies for targeted treatment of lung inflammation,presents the innovative drug delivery systems,and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment.展开更多
文摘In response to the challenges presented by the unreliable identity of the master node,high communication overhead,and limited network support size within the Practical Byzantine Fault-Tolerant(PBFT)algorithm for consortium chains,we propose an improved PBFT algorithm based on XGBoost grouping called XG-PBFT in this paper.XG-PBFT constructs a dataset by training important parameters that affect node performance,which are used as classification indexes for nodes.The XGBoost algorithm then is employed to train the dataset,and nodes joining the system will be grouped according to the trained grouping model.Among them,the nodes with higher parameter indexes will be assigned to the consensus group to participate in the consensus,and the rest of the nodes will be assigned to the general group to receive the consensus results.In order to reduce the resource waste of the system,XG-PBFT optimizes the consensus protocol for the problem of high complexity of PBFT communication.Finally,we evaluate the performance of XG-PBFT.The experimental results show that XG-PBFT can significantly improve the performance of throughput,consensus delay and communication complexity compared to the original PBFT algorithm,and the performance enhancement is significant compared to other algorithms in the case of a larger number of nodes.The results demonstrate that the XG-PBFT algorithm is more suitable for large-scale consortium chains.
基金supported by the National Natural Science Foundation of China(81872810)Program for HUST Academic Frontier Youth Team(2018QYTD13,China)the Fundamental Research Funds for the Central Universities(2018KFYYXJJ019 and 2019KFYRCPY049,China)。
文摘Acute respiratory distress syndrome(ARDS)is characterized by the severe inflammation and destruction of the lung aireblood barrier,leading to irreversible and substantial respiratory function damage.Patients with coronavirus disease 2019(COVID-19)have been encountered with a high risk of ARDS,underscoring the urgency for exploiting effective therapy.However,proper medications for ARDS are still lacking due to poor pharmacokinetics,non-specific side effects,inability to surmount pulmonary barrier,and inadequate management of heterogeneity.The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery.Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy,which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment.Through passive,active,or physicochemical targeting,nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment,thereby showing good therapeutic activity and reduced toxicity.This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy,highlights the strategies for targeted treatment of lung inflammation,presents the innovative drug delivery systems,and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment.
